Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With: thromboembolic

  • Intravenous Immunoglobulin in Dermatomyositis

    Treatment of dermatomyositis with intravenous immunoglobulin (IVIG) resulted in overall better clinical improvement after 16 weeks compared to patients treated with placebo. However, there was a significant number of thromboembolic adverse events in the treatment group. The group of patients treated was a heterogeneous group. However, IVIG now is U.S. Food and Drug Administration-approved for the treatment of dermatomyositis.

  • Rivaroxaban After Transcatheter Aortic Valve Replacement

    In this randomized trial of post-transcatheter aortic valve replacement patients without a separate indication for anticoagulation, a rivaroxaban-based approach was associated with a higher risk of death and thromboembolic complications compared with dual antiplatelet therapy.